Alvotech and Fuji Pharma Extends Agreement for the Commercialization of Four Biosimilars in Japan
Shots:
- The agreement strengthens the ongoing collaboration b/w the companies signed in 2018 to commercialize Alvotech’s biosimilar portfolio in Japan
- Fuji Pharma currently owns a minority stake in Alvotech and now can enter new therapeutic areas following the agreement
- With the extension of the agreement- Fuji Pharma has a leading biosimilar pipeline in Japan. Fuji Pharma will use its strong local expertise in commercializing Alvotech’s portfolio in Japan
Ref: Alvotech | Image: Alvotech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
